SEC filing · 8-K

Sarepta Therapeutics, Inc.: Material agreement

Sarepta Therapeutics entered into a settlement agreement with REGENXBIO, UPenn, and Catalent to resolve patent litigations.

Filed September 23, 2026

Positive for the company

What happened

On September 23, 2026, Sarepta, REGENXBIO, UPenn, and Catalent agreed to resolve pending patent infringement litigations with prejudice.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Sarepta Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.